Catalog No.: PC-21064Not For Human Use, Lab Use Only.
RDN2150 is a potent, selective and covalent ZAP-70 inhibitor with IC50 of 14.6 nM, shows no significant activity against Syk, covalently binds to the C346 residue of ZAP-70.
RDN2150 is a potent, selective and covalent ZAP-70 inhibitor with IC50 of 14.6 nM, shows no significant activity against Syk, covalently binds to the C346 residue of ZAP-70.
RDN2150 exhibits favorable selectivity on a 97-kinase selectivity profiling using the ScanEDGE KINOMEscan assay at 1 uM.
RDN2150 (400 nM, 48h) significantly decreases the frequency of CD69+/CD4+ T cells from 21.3 to 10.8% on CD4+ T cells stimulated by anti-CD3 plus anti-CD28 antibodies.
RDN2150 selectively inhibits CD4+ T cell activation, inhibits the secretion of IFN-γ and IL-17A in the culture supernatant of activated CD4+ T cells, effectively suppresses the phosphorylation of LAT induced by anti-CD3/CD28 stimulation.
RDN2150 ameliorates murine psoriatic skin lesions in the IMQ-induced psoriasis mouse model.
